Plain-English translation of NCT06714513 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new tuberculosis vaccine called (ID93+GLA-SE) to see if it's safe and whether it helps your immune system fight tuberculosis. The vaccine is being studied in adults aged 55 to 74 who are generally healthy or have well-controlled chronic conditions. Researchers will give some people the medication and others a placebo (a dummy injection with no active ingredient) to compare how well the treatment works.
Tuberculosis is a serious infection that affects millions of people worldwide, and the risk increases as we age. Currently, there are no good vaccines to prevent tuberculosis in older adults, so this study aims to fill that gap and help protect aging populations who are most vulnerable to the disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive three injections of either the new vaccine or a placebo at the start of the study, at 4 weeks, and at 8 weeks. You will then have follow-up visits at 1 month, 6 months, and 12 months after your final injection to check for any side effects and to have blood tests that measure how well your immune system is responding. The entire study lasts about one year, and you'll be closely monitored for safety throughout.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
South Korea